pyrazines has been researched along with Left Ventricular Dysfunction in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bond, SJ; Dutka, DP; Hoole, SP; Kydd, AC; McCormick, LM; Read, PA; Ring, LS | 1 |
| Baerts, L; De Keulenaer, GW; De Meester, I; Demolder, M; Hamdani, N; Hervent, AS; Linke, WA; Matheeussen, V; Paulus, WJ; Vandekerckhove, L | 1 |
| Dutka, DP; Heck, PM; Hoole, SP; Khan, FZ; Read, PA | 1 |
| Abramczyk, P; Bil, J; Bugajski, M; Dabrowska-Iwanicka, A; Duszyński, J; Golab, J; Jakóbisiak, M; Kujawa, M; Mackiewicz, U; Maczewski, M; Malinowska, M; Nowis, D; Ratajska, A; Salwa, P; Siński, M; Wieckowski, MR; Wilczyński, GM; Winiarska, M; Wójcik, C | 1 |
| Bax, JJ; Boersma, E; Kam, BL; Krenning, EP; Poldermans, D; Rambaldi, R; Reijs, AE; Rietveld, T; Roelandt, JR; Valkema, R | 1 |
| Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC | 1 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Giaccone, G; Voortman, J | 1 |
1 review(s) available for pyrazines and Left Ventricular Dysfunction
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
3 trial(s) available for pyrazines and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Doppler; Echocardiography, Stress; Electrocardiography; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Ventricles; Humans; Male; Myocardial Ischemia; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2014 |
Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.
Topics: Administration, Oral; Chronic Disease; Coronary Artery Disease; Echocardiography; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrazines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2003 |
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left | 2003 |
4 other study(ies) available for pyrazines and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.
Topics: Animals; Atrial Natriuretic Factor; Compliance; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Heart; Heart Ventricles; Male; Mice; Myocytes, Cardiac; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles; Ventricular Dysfunction, Left | 2014 |
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Topics: Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Stress; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Myocardial Stunning; Pilot Projects; Pyrazines; Reproducibility of Results; Sitagliptin Phosphate; Triazoles; Ventricular Dysfunction, Left | 2010 |
Cardiotoxicity of the anticancer therapeutic agent bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Respiration; Echocardiography; Female; Heart; Heart Diseases; Humans; Male; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Myocytes, Cardiac; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Ventricular Dysfunction, Left | 2010 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |